Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04430179 · ClinicalTrials.gov registry record · Phase 2
Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis
A Phase 2 study of Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis, sponsored by University of South Florida.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04430179 is a Phase 2 study of Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis that is active but no longer recruiting, run by University of South Florida. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04430179, a Phase 2 study of Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis, is active but no longer recruiting, sponsored by University of South Florida.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will investigate the efficacy of dupilumab in patients with severe eosinophilic CRSsNP who are resistant to the conventional treatment with intranasal corticosteroids and have significantly extensive disease involving more than 2 sinuses bilaterally in sinus CT scan and Lund-Mackay sinus (LMK) CT score \>=10 at baseline.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
Study Locations (1)
Florida
- University of South Florida Asthma, Allergy and Immunology - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-12-17 |
| Est. Completion | 2025-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04430179
The ClinicalTrials.gov registry entry for NCT04430179 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04430179 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04430179 about?
NCT04430179 is a clinical study titled "Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis". The investigators will investigate the efficacy of dupilumab in patients with severe eosinophilic CRSsNP who are resistant to the conventional treatment with intranasal corticosteroids and have significantly extensive disease involving more than 2 sinuses bilaterally in sinus CT scan and Lund-Mackay...
What is the current status of trial NCT04430179?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2020-12-17. Estimated completion is 2025-07.
What conditions does trial NCT04430179 study?
This clinical trial studies the following conditions: Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis.
What interventions are being tested in trial NCT04430179?
The interventions under investigation include: Placebo (OTHER), Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT] (DRUG).
Who is sponsoring clinical trial NCT04430179?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04430179 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.